{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Blood samples were to be collected at pre-specified time points and plasma isolated for analysis of pembrolizumab V, defined as the theoretical volume that would be necessary to contain the total amount of administered pembrolizumab at the same concentration that it is observed in the blood plasma. Samples were not collected and this analysis was not performed.","groups":[{"description":"In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.","id":"OG000","title":"Pembrolizumab"},{"description":"In Part 1, participants received placebo IV as post-surgery therapy Q3W.","id":"OG001","title":"Placebo"}],"populationDescription":"As pre-specified by the protocol, pembrolizumab V was not analyzed as planned and no data were collected since by the time of the interim analysis, pembrolizumab PK in melanoma patients had been well characterized and found to be consistent with the overall clinical pharmacology of pembrolizumab characterized across indications.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 8, and then Day 1 of cycle for every 4 cycles afterwards (up to approximately 16 months). Each cycle is 3 weeks.","title":"Volume of Distribution (V) of Pembrolizumab","type":"SECONDARY"}